Kang Hye Bin, Lim Chae Kyu, Kim Jongwan, Han Sang Jun
Department of Biotechnology, College of Fisheries Sciences, Pukyong National University, Busan, Republic of Korea.
Department of St. Mary Pathology and Laboratory Medicine, Busan, Republic of Korea.
Front Med (Lausanne). 2023 Mar 9;10:1030577. doi: 10.3389/fmed.2023.1030577. eCollection 2023.
Renal ischemia/reperfusion (I/R) injury is a major cause of acute kidney injury (AKI) by increasing oxidative stress, inflammatory responses, and tubular cell death. Oxypurinol, an active metabolite of allopurinol, is a potent anti-inflammatory and antioxidant agent. To investigate the therapeutic potential and underlying mechanism of oxypurinol in ischemic AKI, C57BL/6 male mice were intraperitoneally injected with oxypurinol and subjected to renal I/R or sham surgery. We found that oxypurinol-treated mice had lower plasma creatinine and blood urea nitrogen levels and tubular damage (hematoxylin-and-eosin staining) compared to vehicle-treated mice after renal I/R injury. Furthermore, oxypurinol treatment reduced kidney inflammation (i.e., neutrophil infiltration and MIP-2 mRNA induction), oxidative stress (i.e., 4-HNE, heme oxygenase-1 [HO-1], 8-OHdG expression, and Catalase mRNA induction), and apoptosis (i.e., TUNEL or cleaved caspase-3-positive renal tubular cells), compared to vehicle-treated mice. Mechanistically, oxypurinol induced protein expressions of HO-1, which is a critical cytoprotective enzyme during ischemic AKI, and oxypurinol-mediated protection against ischemic AKI was completely eliminated by pretreatment with tin protoporphyrin IX, an HO-1 inhibitor. In conclusion, oxypurinol protects against renal I/R injury by reducing oxidative stress, inflammation, and apoptosis HO-1 induction, suggesting its preventive potential in ischemic AKI.
肾缺血/再灌注(I/R)损伤是急性肾损伤(AKI)的主要原因,可增加氧化应激、炎症反应和肾小管细胞死亡。奥昔嘌醇是别嘌醇的活性代谢产物,是一种有效的抗炎和抗氧化剂。为了研究奥昔嘌醇在缺血性AKI中的治疗潜力和潜在机制,将C57BL/6雄性小鼠腹腔注射奥昔嘌醇,然后进行肾I/R或假手术。我们发现,与肾I/R损伤后接受载体处理的小鼠相比,接受奥昔嘌醇处理的小鼠血浆肌酐和血尿素氮水平以及肾小管损伤(苏木精-伊红染色)更低。此外,与接受载体处理的小鼠相比,奥昔嘌醇处理可减轻肾脏炎症(即中性粒细胞浸润和MIP-2 mRNA诱导)、氧化应激(即4-HNE、血红素加氧酶-1 [HO-1]、8-OHdG表达和过氧化氢酶mRNA诱导)和细胞凋亡(即TUNEL或裂解的caspase-3阳性肾小管细胞)。从机制上讲,奥昔嘌醇诱导了HO-1的蛋白表达,HO-1是缺血性AKI期间一种关键的细胞保护酶,而奥昔嘌醇介导的对缺血性AKI的保护作用被HO-1抑制剂锡原卟啉IX预处理完全消除。总之,奥昔嘌醇通过减少氧化应激、炎症和细胞凋亡以及诱导HO-1来保护肾脏免受I/R损伤,表明其在缺血性AKI中的预防潜力。